Lupin gets USFDA approval of sNDA for SOLOSEC (secnidazole) to treat trichomoniasis
SOLOSEC demonstrated a 92.2 per cent clinically and statistically significant cure rate for patients with trichomoniasis based on…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
supplemental New Drug Application
Lupin presents Phase 3 data for Solosec in female patients with trichomoniasis
The company plans to submit a supplemental New Drug Application for Solosec to the FDA for the treatment of trichomoniasis later…